Christel Bories Joins Ipsen as Deputy Chief Executive Officer

  Christel Bories Joins Ipsen as Deputy Chief Executive Officer

Business Wire

PARIS -- February 27, 2013

Regulatory News:

Ipsen's Board of Directors (Euronext: IPN; ADR: IPSEY) (Paris:IPN), which met
on 26 February 2013, appointed Christel Bories as Deputy Chief Executive
Officer. This appointment will be effective as of 1 March 2013. Working
alongside Marc de Garidel, Chairman and Chief Executive Officer, Christel
Bories will be responsible for accelerating the execution of the Group’s

Marc de Garidel, Chairman and CEO, stated: "I am looking forward to Christel
Bories joining Ipsen by my side. She will provide a new perspective on our
activities and the Group will benefit from her extensive experience both in
France and internationally. In her various positions, Christel demonstrated
strong know-how and proven effectiveness in operational management. Christel
shares our values and her expertise will be valuable to accelerate Ipsen’s

Commenting on her nomination, Christel Bories said: "I am delighted to be
joining the Ipsen group at a key phase of its development. Its reputation for
excellence, the quality of its teams and the potential of its drugs make it
one of the most attractive pharmaceutical companies on the market. I will
bring my industrial and change management experience to service the Group's
strategic ambitions. It is a very inspiring new challenge."

A graduate of top French business school HEC, Christel Bories spent most of
her career in the industrial sector, where she gained solid experience in
global renowned groups. From 1995 to 2003 at Pechiney, she was Director of
Strategy and Management Control, prior to becoming Director of Pechiney
Packaging. In 2004, at the time of the merged with Alcan, Christel Bories took
over as Chairwoman of Alcan Packaging, and then, in 2007, of Alcan Engineered
Products. Finally, in 2008, she was appointed to the helm of Rio Tinto
Engineered Products after the acquisition of Alcan. In 2011, Christel Bories
was Chief Executive Officer of Constellium (formerly Alcan). Since 2011,
Christel Bories has been a member of the Board of Directors of Natixis and
Cercle de l’Industrie, a forum for large industrial companies. She is also
Vice President of French think tank La Fabrique de l’Industrie. Since 2012,
Christel Bories has been Chairperson of the Strategy Committee of Legrand and
a member of the Board of Directors of Smurfit Kappa.

About Ipsen

Ipsen is a global specialty-driven pharmaceutical company with total sales
exceeding €1.2 billion in 2012. Ipsen’s ambition is to become a leader in
specialty healthcare solutions for targeted debilitating diseases. Its
development strategy is supported by three franchises: neurology,
endocrinology and uro-oncology. Moreover, the Group has an active policy of
partnerships.Ipsen'sR&D is focused onitsinnovative and differentiated
technological platforms, peptides and toxins. In 2012, R&D expenditure totaled
close to €250 million, representing more than 20% of Group sales. The Group
has close to 4,900 employees worldwide. Ipsen’s shares are traded on segment A
of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to
the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120
index. Ipsen has implemented a Sponsored Level I American Depositary Receipt
(ADR) program, which trade on the over-the-counter market in the United States
under the symbol IPSEY. For more information on Ipsen,

Ipsen’s Forward Looking Statement

The forward-looking statements, objectives and targets contained herein are
based on the Group’s management strategy, current views and assumptions. Such
statements involve known and unknown risks and uncertainties that may cause
actual results, performance or events to differ materially from those
anticipated herein. All of the above risks could affect the Group’s future
ability to achieve its financial targets, which were set assuming reasonable
macroeconomic conditions based on the information available today.

Moreover, the targets described in this document were prepared without taking
into account external growth assumptions and potential future acquisitions,
which may alter these parameters. These objectives are based on data and
assumptions regarded as reasonable by the Group. These targets depend on
conditions or facts likely to happen in the future, and not exclusively on
historical data. Actual results may depart significantly from these targets
given the occurrence of certain risks and uncertainties, notably the fact that
a promising product in early development phase or clinical trial may end up
never being launched on the market or reaching its commercial targets, notably
for regulatory or competition reasons. The Group must face or might face
competition from Generics that might translate into a loss of market share.

Furthermore, the Research and Development process involves several stages each
of which involves the substantial risk that the Group may fail to achieve its
objectives and be forced to abandon its efforts with regards to a product in
which it has invested significant sums. Therefore, the Group cannot be certain
that favorable results obtained during pre-clinical trials will be confirmed
subsequently during clinical trials, or that the results of clinical trials
will be sufficient to demonstrate the safe and effective nature of the product
concerned. The Group also depends on third parties to develop and market some
of its products which could potentially generate substantial royalties; these
partners could behave in such ways which could cause damage to the Group’s
activities and financial results. The Group cannot be certain that its
partners will fulfill their obligations. It might be unable to obtain any
benefit from those agreements. A default by any of the Group’s partners could
generate lower revenues than expected. Such situations could have a negative
impact on the Group’s business, financial position or performance.

The Group expressly disclaims any obligation or undertaking to update or
revise any forward looking statements, targets or estimates contained in this
press release to reflect any change in events, conditions, assumptions or
circumstances on which any such statements are based, unless so required by
applicable law.

The Group’s business is subject to the risk factors outlined in its
registration documents filed with the French Autorité des Marchés Financiers.


Didier Véron
Vice President, Public Affairs and Corporate Communications
Tel.: +33 (0)1 58 33 51 16
Fax: +33 (0)1 58 33 50 58
Financial Community
Pierre Kemula
Vice President, Corporate Finance, Treasury and Financial Markets
Tel.: +33 (0)1 58 33 60 08
Fax: +33 (0)1 58 33 50 63
Stéphane Durant des Aulnois
Investor Relations Manager
Tel.: +33 (0)1 58 33 60 09
Fax: +33 (0)1 58 33 50 63
Press spacebar to pause and continue. Press esc to stop.